R Squared’s Tango Therapeutics TNGX Stock Holding History

R Squared’s Portfolio TNGX Stock Details TNGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-3,140	Closed	-$9.7K	–	1412
2024 Q4	$9.7K	Buy	+3,140	New	+$14.6K	0.01%	1162

Other funds holding TNGX

TGI

TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

R Squared's TNGX Position: Q1 2025 in Review

R Squared sold out of Tango Therapeutics (TNGX) in Q1 2025, closing a stake of 3,140 shares — an estimated $9.7K sold.

R Squared first reported a position in TNGX in Q4 2024 and held it in 1 quarter. The position peaked at $9.7K in Q4 2024. 122 funds tracked by Wall St. Rank hold TNGX as of Q1 2025.

R Squared reported no remaining Tango Therapeutics position as of Q1 2025 after selling out during the quarter.
R Squared sold 3,140 Tango Therapeutics shares in Q1 2025, an estimated $9.7K.
R Squared first reported a position in Tango Therapeutics in Q4 2024 and held it in 1 quarter.
R Squared's Tango Therapeutics position peaked at $9.7K in Q4 2024.
122 funds tracked by Wall St. Rank held Tango Therapeutics as of Q1 2025.

Based on R Squared's 13F filing for Q1 2025, filed 9 May 2025.